Latest Conference Articles

Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma

At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma

The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma.

PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma

Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.

Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.

Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life

An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.

Web App Boosts Survival for Lung Cancer Patients

Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols.

Cancer Drugs Less Affordable in Poorer Countries Despite Lower Prices

Researchers who set out to understand the affordability of cancer drugs across the globe concluded that lower prices in some poorer countries don’t equate to better access.

Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC

The combination of dabrafenib and trametinib was highly effective as a treatment for patients with BRAF V600E-mutant non–small cell lung cancer.

Nivolumab Delivers Durable Responses in Hodgkin Lymphoma

Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.

Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC

About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Bernard Fox on Significance of Immunoscore Validation Project

Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.

Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer

Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy

A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.

Novel Gastric Cancer Immunotherapy Scores Robust Phase II Results

IMAB362 reduced the risk of death or progression by approximately 50% when added to standard chemotherapy for patients with CLDN18.2-positive advanced gastric cancers.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Rovalpituzumab Tesirine Shows Promising Efficacy for SCLC

Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.

Daratumumab Combo Shows Unprecedented PFS Benefit in Multiple Myeloma

Adding daratumumab to bortezomib and dexamethasone reduced the risk of progression or death by 61%, and doubled response rates compared with the standard 2-drug regimen alone for patients with recurrent or refractory multiple myeloma.

Adding Temozolomide to Radiotherapy Is Effective and Tolerable in Older Adults With Glioblastoma

Adding temozolomide to short-course radiotherapy after surgery boosted overall survival by nearly 2 months, bringing 1-year survival rates up from 22.2% to 37.8% for elderly patients with glioblastoma.

Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

Final Phase III Data Uphold CPX-351 Survival Benefit in AML

CPX-351 reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary AML.

Adding 4-1BB Agonist to Pembrolizumab Safe, Effective Across Solid Tumors

The combination of the 4-1BB agonist utomilumab and the PD-1 inhibitor pembrolizumab was safe and effective as a treatment for patients with advanced solid tumors.

Dr. Hainsworth on Selecting Therapy Based on Genetics

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.

Dr. Cavo on Upfront ASCT in Multiple Myeloma

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology Bologna University School of Medicine, discusses the results of the phase III EMN02/HO95 MM trial, which compared the efficacy of upfront autologous stem cell transplantation versus novel agent-based therapy for the treatment of patients with multiple myeloma.

Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.

Nivolumab Safe, Effective in Early Stage Glioblastoma Study

Single-agent nivolumab demonstrated encouraging signs of activity with a mild adverse event profile for patients with recurrent glioblastoma multiforme.